Top Banner
MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services
24

MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

Dec 22, 2015

Download

Documents

Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

MaineCare & Opioid Treatment

Where we are…How we got here…

Where we are going…

Kevin S. Flanigan, MDMedical Director

Office of MaineCare Services

Page 2: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

Changes throughout the Year• In the beginning of 2012, there were no

restrictions on MaineCare coverage of opioid prescribing.

• The initial law passed in April 2012, created a 45-day lifetime limit on opioid medication coverage.

• The 45-day limit was replaced with the a new Pain Management Policy (PMP), effective 01/01/2013.

Page 3: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

Opioid Use on the Rise: 1991 to 2009

• Prescriptions for opioid analgesics nearly tripled.

• 56% of painkiller prescriptions were given to patients who had filled another prescription for pain, from the same or different providers, within the past month.

(Source: National Institute on Drug Abuse)

Page 4: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

Why Opioids are Widely Used for Pain Management

Opioids: • Are inexpensive.• Control pain which leads to faster recovery.• Improve patient quality of life when properly

used.• Are used to control pain and pain control is

used as a measure of quality, driving increased use of opioids to control pain.

Page 5: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

The Path to Increased Opioid Prescribing

• Opioids improve positive pain management outcomes when used by cancer and post-surgery patients.

• With positive outcomes for this use, opioid prescriptions were expanded to other types of pain management.

• There is a lack of professional consensus concerning patient outcomes in using opioids in the treatment of pain.

Page 6: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

Opioid Coverage and MaineCare

• There are a limited number of covered treatment options for MaineCare members with pain.

• Other pain treatment options are more expensive than opioids.

• Pain control is accepted as a leading quality indicator for positive patient outcomes.

Page 7: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

From Drug Management (45-day limit) to Pain Management

Developing strategies based on type of pain:• Acute (new onset).• Chronic (long term or poor response to other

treatment).• Diagnoses known not to typically respond to

opioid treatment.

Page 8: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

Pain Management: Acute Pain• Acute pain is expected to last less than 8 weeks.• Opioids are allowed for 15 days per 12 month

period.• 14 additional days of opioid treatment may be

covered with Prior Authorization (PA).• A face-to-face visit is required for each prescription

within 96 hours of being written.• Up to three (14 day) refills may be allowed after the

first 15 days.• Surgeons may request a one-time PA for 60 days of

opioid coverage.

Page 9: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

Pain Management: Chronic Pain

• Chronic Pain is expected to last longer than 8 weeks.

• The patient must try one or more interventions from treatment plan.

• The patient must fail to have adequate response to interventions.

• There will be a daily limit on opioid dose.

Page 10: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

Chronic Pain Treatment Options

• Osteopathic Manipulative Treatment (OMT)• Chiropractic Services- 12 per year

maintenance program.• Physical Therapy- 6 visits per year.• Cognitive Behavioral Therapy.• Acceptance Commitment Therapy.

Page 11: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

Chronic Pain Treatment PlanExceptions

Each patient is required to complete at least one chronic pain treatment option.

Exceptions to completing the chronic treatment plan are:•The patient has completed at least 50% of plan with no progress or worsening symptoms.•The patient is not a candidate for treatment options due to cognitive loss or other health related issues.

Page 12: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

Opioid Dosing LimitsMinimum

•30mg or less of Morphine Sulfate equivalent- exempt from PA process

Maximum

•<300mg of Morphine Sulfate equivalent- maximum allowed dose

Page 13: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

Chronic Pain: Diagnoses No Longer Covered

Discontinuing MaineCare coverage for selected diagnoses:

• Headaches• Chronic back and neck pain• Fibromyalgia

Page 14: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

Second Opinion Program: PA is Required for Chronic Use

The following patients will need a second opinion before opioid prescriptions are authorized:

• Patients with illness known to have poor response to opioids such as headaches, neck & back pain, and Fibromyalgia.

• Physicians providing a second opinion must be from a different site.

Page 15: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

PA is Not Required for Selected Situations

• End-of-life care• Pain caused by cancer• Nursing Home patients• Inpatient care• HIV/AIDS

Page 16: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

Acute Pain Case Discussion

Page 17: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

Acute to Chronic Pain Case Discussion

Page 18: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

Current Chronic Pain Case Discussion

Page 19: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

New Onset Chronic Pain Case Discussion

Page 20: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

Non-covered Diagnoses Management

Page 21: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

Working with Opioid Prescribers is a Fundamental Goal of MaineCare’s PMP

• Evaluate effective use of opioids by looking at the patient behavior patterns.

• Inform physicians about their own treatment patterns in comparison to peers.

• Outreach to individual providers concerning opioid prescribing patterns.

• Follow-up to encourage providers to bring prescribing patterns in line with peers.

Page 22: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

PMP: Outreach Steps

• First letter- “just to let you know.”• Second letter- educational opportunities

available.• Third letter- request letter of explanation or letter

explaining corrective plan within 14 days.• Fourth letter with accompanying phone call- if no

action forthcoming, referral to Board of Licensure vs. change of Provider Agreement.

Page 23: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

Concluding Remarks: Working Together

Leadership at DHHS & OMS has welcomed input from the medical community and from patient advocates when creating a PMP for MaineCare coverage. This collaborative approach has lead to a policy that is reflective of quality care, yet allows appropriate use of opioid medications where indicated.

Page 24: MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.

For More Information

For more information about MaineCare’s PMP, contact MaineCare’s Medical Director, Kevin Flanigan, MD at:

[email protected](207) 287-1827